Clinical Trial Update: Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of PD-0332991 (palbociclib) in advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• PD-0332991 (palbociclib) (palbociclib)

Snippet

Sponsor: Institut Bergonié | Conditions: Advanced Gastrointestinal Stromal Tumors | Phase 2 | Status: COMPLETED | Results posted: 2021-01-20